Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sanofi (SNY - Analyst Report) recently announced encouraging data from two phase III studies (ENGAGE and ENCORE) evaluating the use of its oral candidate, eliglustat tartrate, for Gaucher disease type I.   

The randomized, double-blind, placebo controlled ENGAGE phase III study enrolled 40 treatment-naïve patients with Gaucher disease type I. Results from the study revealed a statistically significant improvement in spleen size at nine months for patients treated with eliglustat tartrate compared to those in the placebo arm.

Additionally, improved hemoglobin levels, platelet levels and liver volumes were observed in patients in the eliglustat tartrate arm compared to patients treated with placebo.

Sanofi also reported data from the second phase III study, ENCORE. The randomized, open-label study enrolled 160 adults with Gaucher disease type I. The study compared eliglustat tartrate with Sanofi’s Cerezyme, the current standard of care for Gaucher disease type I. Eliglustat tartrate demonstrated non-inferiority to Cerezyme and met the primary endpoint of the study.

Our Take

Eliglustat tartrate, if approved, will provide a convenient treatment option to Gaucher disease type 1 patients as compared to Cerezyme, which is administered through intravenous infusions. We note that Sanofi is looking to develop its pipeline to combat the generic threat that is faced by several of its products.

Sanofi carries a Zacks Rank #3 (Hold) in the short run. Pharma companies that currently look better-positioned include Astellas Pharma (ALPMY), Eli Lilly and Company (LLY - Analyst Report) and Bayer (BAYRY - Analyst Report). All three companies carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.28 +14.66%
ANI PHARMACE ANIP 24.64 +13.97%
E HOUSECHINA EJ 11.01 +9.44%
CANADIAN SOL CSIQ 26.90 +6.87%
KNIGHTSBRIDG VLCCF 12.47 +5.50%